The National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH) recently issued a new suite of funding opportunities for neurotherapeutics development. The goals are to build a contiguous bridge from basic science, accelerate the advancement of promising projects to clinical testing with the contributions of multidisciplinary teams, and enhance hand-off to subsequent funders.
The unmet medical need for therapeutics that ameliorate the burden of neurological disorders is well documented in this issue's accompanying articles (Jensen and Amara, 2014) . For over 60 years, NINDS has been arguably the largest single funder of basic neuroscience research, which is the raw material that feeds the translational and clinical neurology engines of academia and industry alike (Koroshetz and Landis, 2014) . By contrast, the role that federal agencies such as NINDS (and NIH) should play in the translational arena is less clear, and there is some debate whether it would be prudent to leave this area entirely to the pharmaceutical and biotechnology industries. The NIH community has recently focused many of its efforts on translational pipeline issues. The youngest of the NIH institutes, The National Center for Advancing Translational Sciences (NCATS), was birthed with the intent of addressing, in a disease-agnostic manner, many of the issues mentioned above. NCATS has implemented various new innovative programs, such as the New Therapeutics Uses program that seeks to find new uses for agents that have undergone significant research and development by industry, including safety testing in humans, and the Tissue Chip for Drug Screening initiative, which aims to develop 3D human tissue chips to predict whether a candidate drug, vaccine, or biologic agent is safe or toxic in humans in a faster and more cost-effective way than current methods. The National Institute of Mental Health has tackled head-on the concern of high failure rates of later-stage clinical trials in psychiatry, coupled with them often being noninformative (http:// sfari.org/news-and-opinion/news/2012/ funding-agency-seeks-success-in-fastfail-clinical-trials), by starting the ''FastFail Trials'' (FAST) contract mechanism. FAST seeks to not only identify compounds that merit more extensive testing but also to identify targets in the brain for the development of additional candidate compounds. The FAST trials focus on assessing target-engagement and obtaining pharmacodynamic readouts, principles that the NINDS programs also emphasize, as described below.
The lack of adequate neurotherapeutics is compounded by the emerging trend that treatments for neurological disorders have particularly long clinical development and approval times (8.8 to 11 years) and a low clinical approval success rate (8%) (Miller, 2010; Kaitin and Milne, 2011) . Furthermore, new treatment ideas that typically stem from investments in basic research need time to mature before they have mitigated enough risk to be embraced by the biopharmaceutical industry. With such inherent risks in terms of time and money, the industry has dialed back early-stage investments in neurotherapeutics development (Kaitin and Milne, 2011; Hyman, 2012) . There is a clear need for projects to be incubated during this high-risk phase of innovation before they will be adopted by the private sector. Given the current industry landscape, NINDS views its commitment to translational research as critical to bridging the current gaps in both optimal capitalization on basic science advancements and in consistent uninterrupted progression of novel treatment ideas through the neurotherapeutics pipeline. This article outlines the historical overview of NINDS translational programs, the new programs that have been initiated to better address the gaps (see http://www.ninds.nih. gov/funding/areas/translational_research/ funding_programs_researchers.htm for complete details on these programs), and NINDS's plans for future enhancements.
Programmatic Experimentation
In 2002, NINDS leadership initiated a set of focused translational grant programs with the aim of fostering the preclinical development of therapeutics in the nonprofit and small business sectors (Finkelstein et al., 2002) . These programs were subsequently endorsed with enthusiasm by an external advisory panel convened in 2007 to assess NINDS's translational programs. Noting that the focus of NIH study sections on hypothesis-driven research was not well suited to the needs of therapeutics development, NINDS implemented a specialized peer review environment that included translational experts from academia and industry to serve on study sections. They also took advantage of a cooperative agreement grant mechanism (U01), which allows the use of scientific milestones to gate project progression. This U01 program was complemented by a program that uses exploratory/development grants (tR21) to support projects whose objective, among many, was to prepare for entry into the U01 program. In parallel, NINDS also spearheaded a contract-based approach to develop a therapeutic to treat spinal muscular atrophy (SMA) (Dolgin, 2012) . The experience gained from the SMA project then led in 2011 to the establishment of the Blueprint Neurotherapeutics Network (BPN) Grand Challenge, a trans-NIH initiative that enables researchers to access a network of contract research organizations (CROs) and industryseasoned consultants to help discover and develop small-molecule drugs (Heemskerk et al., 2012) . During the last decade, NINDS has continued to optimize these programs, sunsetting those that did not work or that had met their goals, while incrementally improving existing programs.
These programs delivered some important successes. Specifically, the tR21 programs led to the development of several novel preclinical models and tools applicable to neurotherapeutics development (see Frost et al., 2012 and Xu et al., 2011 for select examples). Several of the U01 projects reached their goal of an Investigational New Drug (IND) or Investigational Device Exemption (IDE) application with the Food and Drug Administration (FDA) and have entered early human clinical testing (http://www.ninds.nih.gov/funding/areas/ translational_research/grants/otr_active_ projects.htm). Other U01 projects were discontinued upon failing to meet their scientific milestones. Such discontinuations represent cost savings of taxpayer dollars for NINDS. They also have the potential to be important learning opportunities to the field at large, since a robust negative result can be valuable in discouraging further unnecessary investment in that specific therapeutic or scientific hypothesis. In addition, the BPN has successfully launched 15 therapy development projects, established and deployed a network of CROs, and engaged consultants with significant industry experience and program staff with disease and drug discovery and development expertise to complement the strengths of the principal investigators.
These successes notwithstanding, NINDS has learned valuable lessons that provided a rich experience base to help develop a new suite of programs that build on the strength of past successes and address some of the key challenges encountered along the way. For example, the experience of investigators and NINDS program staff indicated that it was cumbersome to have a one-sizefits-all program to support development of small molecules, biologics, and devices, given that the requirements vary greatly by modality both in the preclinical arena as well as from a regulatory perspective. Furthermore, achieving the end goal of an IND or IDE did not, in many cases, then result in those candidate therapeutics entering clinical testing. The tR21 program, while productive in supporting the generation of important reagents and tools, was not adequate in either duration or funding level to enable investigators to assemble the comprehensive package required to transition their exciting basic science findings to a stage where they were competitive for entry into the U01 program. The BPN program allowed projects to enter only if they still required lead optimization, thereby precluding the entry of worthy projects that had progressed beyond the medicinal chemistry stages of preclinical development. In 2013, these observations and other lessons led NINDS to perform an extensive internal analysis and program development effort culminating in the July 2014 announcement of the first set of new translational funding programs.
New NINDS Translational Funding Programs
The new NINDS programs seek to operationalize the principle that translation begins and ends with the patient, and as such, we must strive to identify the target(s)/pathway(s) the therapeutic is seeking to modulate and be able to measure the effect of such modulation in both preclinical models and the clinic. The other key principle that is intrinsic to the design of the programs and how proposals will be evaluated is the need for cross-disciplinary collaboration with the end-goal in mind. The new programs are tailored to the different treatment modalities. The Cooperative Research to Enable and Advance Translational Enterprises (CREATE) for Biotechnology Products and Biologics (CREATE Bio) is dedicated to biotechnology product-and biologicsbased therapies, which broadly include modalities such as peptides, proteins, oligonucleotides, gene therapies, and cell therapies. The CREATE Devices program provides support for projects that focus on preclinical and pilot clinical studies for therapeutic devices. NINDS also decided to support all future smallmolecule therapy development projects in neurology solely through the BPN mechanism, because it was clear that the advantages of conducting the work through this mechanism allowed for an additional level of quality and rigor compared to what is achievable through the predecessor U01 grant mechanism. In addition, BPN program staff have built up a nation-wide virtual network of contractors and consultants with extensive professional drug discovery and development experience to support the following aspects of therapeutic development: medicinal chemistry, data management, pharmacology and toxicology testing, formulation and manufacturing, bioactivity/efficacy studies, and Phase I clinical trials. The BPN program was reissued in July 2014 with several new features and changes that are detailed below. At present, it is not practical for NINDS to develop a similar network mechanism for devices or for each of the submodalities covered by the CREATE Bio program, and therefore, those programs will continue to operate using the cooperative agreement grant mechanisms. Furthermore, each of the three programs also features a parallel small business track to allow eligible small businesses to more favorably compete for funding from the congressionally mandated set-aside funds for supporting small business innovation.
CREATE Bio: Two-Tier Program Enabling a Broad Range of Modalities
The CREATE Bio program includes two tracks-a Discovery Track that supports lead optimization to obtain a candidate appropriate for entering the Development Track and a Development Track that supports IND-enabling studies for the candidate, as well as early-phase clinical trials ( Figure 1A ). Discovery Track projects are funded for up to 4 years through the U01 or Small Business Innovation Research (SBIR) U44 cooperative agreement award mechanisms, while Development Track projects are funded for up to 5 years through UH2/UH3 or SBIR U44 cooperative agreement award mechanisms. One key feature of the Discovery Track is that projects need to propose end goals that match the entry criteria for the Development Track, as the intention is to create a contiguous therapeutic pipeline. Furthermore, as projects meet the penultimate year milestones in the Discovery Track, they will be eligible to apply for Development Track funding. Therefore, a project that successfully obtained Development Track funding on the strength of the data generated during the Discovery Track would be able to continue seamlessly with no lapse in funding when switching from the Discovery to the Development Track; such gaps in funding while transitioning from one funding mechanism to another were all too common in the past, even for eminently worthy projects. The expectation in the CREATE Bio Discovery Track is that projects will identify and characterize an optimized candidate that has sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application. These features will prepare the project for entry into the CREATE Bio Development track for further development toward filing for an IND. The CREATE Bio Development Track supports Chemistry, Manufacturing, and Controls activities and, depending on the modality, current Good Manufacturing Practices production of drug substance that are stage appropriate and IND-enabling studies and to conduct both late-stage preclinical toxicology studies and early human clinical trials. Understanding the need to develop target engagement markers, which help increase the probability of hypothesis testing and success in clinical development, the CREATE Bio program allows the validation of target engagement markers in conjunction with therapeutic development. In addition, the entry criteria also take into consideration the challenge encountered in some neurological disorders where the preclinical efficacy models at hand may not reflect the clinical etiology of the disorder: In the absence of preclinical in vivo efficacy measures that are clinically relevant in the field, projects can apply by presenting evidence of in vivo target engagement at the clinically intended site of action.
CREATE Devices: Separate Tracks for Distinct Regulatory Pathways Device development has been split into three tracks, primarily to cater to the rather specific regulatory pathways at the FDA and their attendant requirements ( Figure 1B) . Separating projects into these tracks will also allow the peer review process to perform more relevant and comparative evaluations, whereas, in the past, projects with these three rather disparate end goals were reviewed en masse, leading to inaccurate/misleading assessments of feasibility, innovation, and commercial potential. The first track, entitled ''Translational and Clinical Studies to Inform Final Device Design,'' will support development of a device to test scientific hypotheses that are not feasible or practical to conduct in animal models but are critical to enable nextgeneration devices. Preclinical work should lead to an IDE to support a clinical study, or a Non-Significant Risk (NSR) study that does not require an IDE. The second track, entitled ''Translational and Clinical Studies on the Path to 510(k) premarket submission,'' will support preclinical studies and the subsequent IDE-enabled or NSR clinical studies. It is expected the immediate next steps upon completion of the clinical study will be a 510(k)/510(k) De Novo submission or a larger clinical trial that will also lead directly to a 510(k)/510(k) De Novo submission. The third track, entitled, ''Translational and Early Feasibility Studies on the Path to Pre-Market Approval (PMA) or Humanitarian Device Exemption (HDE),'' will support applications to pursue preclinical studies for an IDE submission, with the option of also supporting the subsequent Early Feasibility Study. It is expected the immediate next steps upon completion of the Early Feasibility Study will be a full Feasibility Study and a Pivotal Trial, which provides evidence for marking approval, in support of a PMA or HDE. Projects can be funded in the CREATE Devices program through the UH2/UH3 or the SBIR U44 cooperative agreement mechanism for a maximum of 5 combined years across the two phases of the program. (Heemskerk et al., 2012) are (a) the ability of investigators to choose a flexible blend of activities that are funded in their own laboratories as opposed to having them conducted at NIH-funded CROs, (b) multiple entry points for projects to access BPN resources ( Figure 1C ), (c) the addition of a preparatory phase at the start of the project to complete all studies necessary to meet rigorous criteria for initiating medicinal chemistry optimization or preclinical development, and (d) the introduction of an SBIR track for eligible small businesses. Participants in the BPN will continue to benefit from access to the BPN CRO network, industry-seasoned consultants, and program staff. Participants will also continue to receive assignment of the intellectual property rights to compounds discovered and developed within the program.
Priming the Pump
The second and third sets of programmatic changes will be released in December 2014 and mid-2015 and will replace the tR21 program with a suite of funding opportunities, rebranded as Innovation Grants to Nurture Initial Translational Efforts (IGNITE). The IGNITE suite of funding opportunities is focused on enabling grantees to build upon their innovative basic science finding to successfully meet the entry criteria for the CREATE Bio and BPN programs described above. The expectation is that IGNITE projects will directly feed into the various entry points in the CREATE Bio and BPN programs, thereby creating a more contiguous flow into the preclinical translational pipeline than previously observed (Figure 2) . The IGNITE programs to be launched in December 2014 will focus on supporting (a) the development of new in vitro and ex vivo assays and iterative screening efforts to identify and characterize novel therapeutic agents for neurological disorders and (b) the implementation of pharmacodynamics (PD), pharmacokinetics (PK), and in vivo efficacy studies to demonstrate that proposed therapeutic agents are appropriately chosen for further development as a treatment of a neurological disorder. The correlation of PK and PD measures greatly increases the confidence in, and further understanding of, in vivo efficacy data by exploring the relationship between the concentration of the agent at the site of action and the resulting in vivo readouts (Cook et al., 2014; Day et al., 2009 ). The two additional IGNITE programs slated for release in mid-2015 will focus respectively on (a) funding translatable animal models and quantifiable markers of target engagement applicable in humans and (b) neuroscience-focused translational platform technology development that enables and accelerates drug discovery for neurological disorders (e.g., overcoming blood-brain barrier impermeability).
Gaps that Remain NINDS recognizes that the programmatic changes described above do not as yet address a few key outstanding needs in the neurotherapeutics ecosystem. First, there is the need for reliable, clinically relevant surrogate readouts of efficacy that can allow for the conduct of shorter and cheaper early-phase clinical trials (Paul et al., 2010) . The Alzheimer's Disease Neuroimaging Initiative (Cummings, 2010) represents the type of effort required to make progress in this area. Second, there is the need for appropriate education and relevant hands-on training for neuroscientists who wish to pursue work in the translational arena. This topic is dealt with in more detail in the accompanying article (Jensen and Amara, 2014) . Third, given NINDS's leadership role in highlighting the need for rigor in preclinical research (Landis et al., 2012) , the studies funded by the new programs will be expected to demonstrate that they are sufficiently powered and designed with the experimental and statistical rigor necessary to confer a high degree of confidence in the results. In addition, there should be sufficient information available about study design, execution, analysis, and interpretation to allow for a full assessment and replication of these experiments. However, in cases where proposals suggest promising preliminary data but do not show satisfactory evidence of a rigorous approach to experimental design and analysis, there is currently no facile means in place to perform a quick, independent replication or a set of small and rapid ancillary studies (e.g., brain/plasma drug level measurements) to support the existing data package in the proposal. Such studies would not merit a standalone grant application but would be viewed as important to NINDS as it evaluates the financial risk involved in investing larger amounts of money required for latestage preclinical development. This is an The IGNITE programs dovetail with the entry points of the CREATE Bio and BPN programs to create a seamless translational funding pipeline.
area of need that NINDS will seek to address, specifically for neurology in the near future, in conjunction with trans-NIH efforts to address this important issue (Collins and Tabak, 2014) .
Cultivating Partnerships for the Future The search for new medicines is long, arduous, and perilous. The journey is not a sprint, but a marathon, but not one that is run by one person or even one organization. It is a relay race, where several runners, each with skills and temperaments optimal to the terrain encountered, run different portions of the race. The basic scientist begins by exploring numerous forks on the road, many leading to cliffs and dead-ends. Once a viable path is discovered, the baton then passes to the translational experts who then have to run a steeplechase filled with medicinal chemistry hurdles, pharmacology stonewalls, and toxicology water jumps. The clinicians then have to pick up the baton and run a long final stretch that is carefully regulated by race officials to ensure that whatever crosses the finish line has an acceptable benefit-to-risk ratio for the patients. For this race to be completed, team collaboration is paramount: no relay race is ever completed if the baton is dropped or one runner does not overlap with the other. The success of translation from basic science findings to clinical relevance depends greatly on interdisciplinary interactions, requiring a therapy development team comprised of experts from academia and industry (Skarke and FitzGerald, 2010) . With this philosophy in mind, for the new programs NINDS has initiated, investigators are routinely encouraged during the application phase to expand their expertise base and enhance the caliber of the team, both of which are key determinants of success in the peer review process. The approach is also reflected internally at NINDS, where these milestone-driven programs are managed in ways to benefit from input from teams of multidisciplinary experts drawn from the NINDS staff and supplemented as needed by external consultants. NINDS spends approximately $100 million annually through its various targeted translational funding programs and more than three times that amount on clinical trials. However, these investments are far from adequate to advance effective therapies all the way to the marketplace for the hundreds of disorders that fall under the NINDS mission. Rather, NINDS hopes that its translational funding de-risk projects so that other investors (venture capital, biopharmaceutical companies, angel investors, disease foundations, and other funding programs from NINDS/NIH/federal or state agencies) find the projects worthy of further investment. Only by cooperating in the ecosystem with the other essential participants will NINDS be able to achieve the part of its mission that speaks to reducing the burden of neurological disorders. To this end, the CREATE and BPN programs are designed to meet the key attributes of a therapeutic that would garner a positive evaluation during the due diligence phase of a private sector acquisition or partnership process. NINDS has also begun to interact directly with potential downstream investors in order to better understand their expectations regarding the attributes of an NINDSfunded asset that would attract a cofunding arrangement or acquisition. Such discussions have already led to cofunding arrangements for a few projects. In these interactions, the NINDS would also like to raise awareness of its existing portfolio of peer-reviewed translational projects (http://www.ninds.nih. gov/funding/areas/translational_research/ funding_programs_researchers.htm) in a more systematic manner. This would augment the efforts of the grantees and their institutions/companies, which can often be limited by time, experience, and/ or cost associated with the specialized, labor-intensive outreach necessary to develop productive partnerships. NINDS is also actively providing guidance and support to its current grantees to prepare them for such partnership discussions. It is hoped that these efforts, in conjunction with the new programs described herein, will improve the quality of the neurotherapeutic pipeline such that the private sector entities that have recently fled this space will re-engage with vigor.
CONCLUSIONS
NINDS has consistently demonstrated its willingness to explore new approaches to foster innovative research across the entire continuum of basic, translational, and clinical disciplines, for example, by establishing the NeuroNext clinical network (Heemskerk et al., 2012) ; the Exceptional, Unconventional Research Enabling Knowledge Acceleration (EUREKA) program (www.sciencedaily.com/releases/2013/ 09/130903113258.htm); or the more recent initiatives for encouraging fundamental neuroscience research with no explicit link to a specific disease (Koroshetz and Landis, 2014) . This renewed emphasis on fundamental science (Collins, 2012) , coupled by the newly launched BRAIN initiative (Insel et al., 2013) , augurs well for the enrichment of the raw materials that will prime the pump of neurotherapeutics discovery and development. The CREATE, BPN, and IGNITE programs described herein represent the latest efforts by NINDS to adapt to current challenges in the neurotherapeutics ecosystem to ensure that new discoveries do not languish or stall but are smoothly and rapidly advanced toward the clinic. These new programs will continue to be evaluated both internally and through appropriate independent groups to ensure that they continue to serve the needs of the neurology community and, through them, to eventually address the hopes and expectations of people suffering from the burden of neurological disorders.
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